Baxter International Hits New 52-Week Low at $16.36

Baxter International, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 16.36 as of March 19, 2026. This significant decline marks a stark contrast to its 52-week high of USD 34.52, reflecting a challenging year for the company. Over the past year, Baxter's stock has plummeted by 49.35%, while the S&P 500 has seen a positive performance of 16.41%. Financial metrics indicate a tough landscape for Baxter, with a price-to-earnings (P/E) ratio of 46.00 and a return on equity of just 4.23%. The company has reported negative results for three consecutive quarters, with operating cash flow at its lowest point of USD 765 million and net sales declining by 26.29% to USD 2,810 million. Additionally, pre-tax profit has fallen by 45.07%, highlighting the company's struggles in maintaining profitability. Baxter's high debt-to-equity ratio of 1.23 and a debt-to-EBITDA ratio of 3.86 times further complicate its financial position, indicating a low ability to service debt. As the company navigates these challenges, its performance continues to lag behind the broader market.